Evidence based venous thromboprophylaxis in patients undergoing total hip replacement (THR), total knee replacement (TKR) and hip fracture surgery (HFS)

被引:1
|
作者
Autar, Ricky [1 ]
机构
[1] De Montfort Univ, Fac Hlth & Life Sci, Charles Frears Campus,266 London Rd, Leicester LE2 1RQ, Leics, England
关键词
Venous thromboembolism; Venous thromboprophylaxis; Deep vein thrombosis; Pulmonary embolism; Total hip replacement; Total knee replacement; Hip fracture surgery; Mechanical prophylaxis; Pharmacological prophylaxis; Venous thromboprophylaxis guidelines;
D O I
10.1016/j.ijotn.2011.01.001
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Patients undergoing total hip, knee replacement and hip fracture surgery are at high risk of developing venous thromboembolism. Incidence of deep vein thrombosis ranges from 40% to 70% and 1% to 7% for fatal pulmonary embolism. Venous thromboprophylaxis comprises mechanical and pharmacological intervention but for added protection in major orthopaedic surgery, most national and international guidelines advise a combined regimen of both modalities. Reportedly, 40% of such patients do not receive pharmacological prophylaxis because of the increased risk of bleeding. When considering pharmacological prophylaxis, a trade off between the benefits of reducing venous thromboembolism and the potential harms of bleeding and haematoma formation must be balanced. Anti-embolism stockings, intermittent pneumatic pump and foot impulse devices are the main mechanical methods but are often collectively addressed as mechanical prophylaxis as no difference in efficacy exists between these devices. The National Institute for Health and Clinical Excellence advises that one of those devices be commenced preoperatively and continued until the patients have no significant reduced immobility. Anti-embolism stockings (knee or thigh) are to be applied with caution. Mechanical prophylaxis is particularly important in hip/knee and hip fracture surgery, when patients are not protected by pharmacological prophylaxis. Unfractionated heparin, low molecular weight heparin, pentasaccharide fondaparinux and old and new oral anticoagulants are the mainstay of pharmacological prophylaxis. In the absence of contraindication, it is recommended that pharma-cological prophylaxis is timely initiated postoperatively. Extended pharmacological prophylaxis is recommended for 28-35 days for hip replacement and hip fracture surgery and 10-14 days for knee replacement surgery. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:145 / 154
页数:10
相关论文
共 50 条
  • [1] Thromboprophylaxis in patients undergoing total hip replacement
    Brenkel, IJ
    Cook, RE
    HOSPITAL MEDICINE, 2003, 64 (05): : 281 - 287
  • [2] Adherence with Injectibal Prophylaxis for Venous Thromboembolism (VTE) Following Total Hip (THR) and Total Knee (TKR) Replacement Surgery: Complete Registry
    Semchuk, William M.
    Backstein, David
    Stewart, John
    Dessouki, Esmat
    Kwan, Mary
    Lavoie, Pauline
    Valois, Maria
    Mills, Allan
    Eikelboom, John W.
    BLOOD, 2009, 114 (22) : 233 - 233
  • [3] A review of venous thromboprophylaxis in patients undergoing hip fracture surgery (HFS)
    Autar, Ricky
    INTERNATIONAL JOURNAL OF ORTHOPAEDIC AND TRAUMA NURSING, 2010, 14 (02) : 88 - 95
  • [4] Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery
    Baser, Onur
    Supina, Dylan
    Sengupta, Nishan
    Wang, Li
    Kwong, Louis
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (02) : 423 - 429
  • [5] Patterns of Pre-Operative Anemia Screening (PAS) in Elective Total Hip Replacement (THR) or Total Knee Replacement (TKR) Surgery
    Ellis, L.
    Bailey, R.
    Forlenza, J.
    Senbetta, M.
    Blumberg, P.
    TRANSFUSION, 2010, 50 (11) : 2510 - 2510
  • [6] Impact of venous thromboemolism in US Medicare patients undergoing total hip and total knee replacement surgery
    Baser, O.
    Supina, D.
    Sengupta, N.
    Wang, L.
    Kwong, L. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 788 - 789
  • [7] Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery
    Baser, Onur
    Supina, Dylan
    Sengupta, Nishan
    Wang, Li
    Kwong, Louis
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (17) : 1438 - 1445
  • [8] Total hip and knee replacement (THR/TKR): Preoperative function and postoperative costs.
    St Pierre, Y
    Fortin, PR
    Ferland, D
    Katz, JN
    Tanzer, M
    Liang, MH
    Mahomed, NN
    Clarke, AE
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S328 - S328
  • [9] Economics of Thromboprophylaxis in Total Hip Replacement Surgery
    Jeff Harrison
    David J. Warwick
    Joanna Coast
    PharmacoEconomics, 1997, 12 : 30 - 41
  • [10] Cost-effectiveness of apixaban prophylaxis for venous thromboembolism (VTE) in total knee and hip replacement (TKR/THR)
    Rublee, D.
    Simon, T.
    Migliaccio-Walle, K.
    Merikle, E.
    Caro, J.
    Marchant, N.
    Drost, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 194 - 194